ArticleClinical journal of the American Society of Nephrology : CJASN2009
Bone disease in medullary sponge kidney and effect of potassium citrate treatment.
Article in Clinical journal of the American Society of Nephrology : CJASN, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 43 citations in OpenAlex.
- Correction of metabolic acidosis with potassium citrate in renal transplant patients and its effect on bone quality.Clinical journal of the American Society of Nephrology : CJASN · 2012Trial
- Porous perspectives: a comprehensive review of medullary sponge kidney.International urology and nephrology · 2025Review
- Comparison of the bone mineral density status of patients with kidney stones stratified by stone composition.World journal of urology · 2024Article
- Article
- Distal renal tubular acidosis: a systematic approach from diagnosis to treatment.Journal of nephrology · 2021Review
- Sphingomyelin and Medullary Sponge Kidney Disease: A Biological Link Identified by Omics Approach.Frontiers in medicine · 2021Article
- Ambiguous clear cell carcinoma in medullary sponge kidney: A case report.Asian journal of urology · 2020Article
- Proteomic Analysis of Urinary Extracellular Vesicles Reveals a Role for the Complement System in Medullary Sponge Kidney Disease.International journal of molecular sciences · 2019Article
- ChlorthalidoneAnnals of translational medicine · 2019Article
- Nephrocalcinosis in adolescent girl with medullary sponge kidney and mild hemihypertrophy: A case report.Medicine · 2019Article
- Association of medullary sponge kidney and hyperparathyroidism with RET G691S/S904S polymorphism: a case report.Journal of medical case reports · 2018Article
- Incomplete Distal Renal Tubular Acidosis and Kidney Stones.Advances in chronic kidney disease · 2018Review
- Article
- Abnormal distal renal tubular acidification in patients with low bone mass: prevalence and impact of alkali treatment.Urolithiasis · 2017Article
- Kidney stones.Nature reviews. Disease primers · 2016Review
- The relationship between calcium kidney stones, arterial stiffness and bone density: unraveling the stone-bone-vessel liaison.Journal of nephrology · 2015Article
- Nephrolithiasis-associated bone disease: pathogenesis and treatment options.Kidney international · 2011Review
- Long-term treatment with potassium citrate and renal stones in medullary sponge kidney.Clinical journal of the American Society of Nephrology : CJASN · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesIn medullary sponge kidney (MSK)-a common malformative renal condition in patients with calcium nephrolithiasis-hypercalciuria, incomplete distal renal tubular acidosis, and hypocitraturia are common. Clinical conditions with concomitant hypercalciuria and/or incomplete distal renal tubular acidosis are almost invariably associated with bone disease, making osteopathy highly likely in MSK, too. Patients with MSK have never been investigated for osteopathy; neither has the potential effect of potassium citrate administration (CA) on their urinary metabolic risk factors and on bone mineralization. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: These issues were retrospectively analyzed in 75 patients with MSK and primary stone risk factor (PSRF; hypercalciuria, hypocitraturia, hyperuricosuria, and/or hyperoxaluria) on an outpatient basis; 65 received CA (2.9 +/- 0.8 g/d), whereas 10 received only general "stone clinic" suggestions. The 24-h urinary excretion of calcium, phosphate, oxalate, uric acid, and citrate; morning urine pH; serum biochemistry; and bone mineral density were investigated at baseline and at the end of follow-up (78 +/- 13 and 72 +/- 15 mo in groups A and B, respectively).
resultsCA led to a significant rise in urinary pH and citrate and decreased urinary calcium and phosphate (all P < 0.001). Patients with MSK and PSRF had reduced bone density. Bone density improved significantly in the group that was treated with oral CA.
conclusionsBone disease is very frequent in patients with MSK and concomitant PSRF. Long-term CA improves bone density. The concurrent effects of treatment on PSRF suggest that the subtle acidosis plays a pivotal role in bone disease and hypercalciuria in patients with MSK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.